IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2819
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.3B
David T. Hung
Nuvation Bio Inc. focuses on the development of therapeutic candidates for oncology. Lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Company was formerly known as RePharmation Inc.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NUVB Nuvation Bio Inc. | 45 | 37 | 47 | 75 | - | - | -64.2% | -34.8% | 11.2% | -2568.9% | -2260.2% | 814.3% | 0.0% | 14.0x | $1.3B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Nuvation Bio Inc. (NUVB) receives a "Reduce" rating with a composite score of 44.9/100. It ranks #2819 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
David T. Hung
Chief Executive Officer
Labor Force
60
37
21
42
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NUVB
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NUVB.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 37 | 14 | +23ALPHA |
| MOMENTUM | 75 | 77 | -2NEUTRAL |
| VALUATION | 47 | 25 | +22ALPHA |
| INVESTMENT | 21 | 3 | +18ALPHA |
| STABILITY | 42 | 22 | +20ALPHA |
| SHORT INT | 27 | 12 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -64.2% (sector -2.5%)
GM 11% vs sector 43%, OM -2569% vs sector 1%
Capital turnover N/A, R&D intensity 384.1%
Rev growth 814%, 5yr history
Interest coverage -8.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Nuvation Bio Inc. receives a Reduce rating from our analysis, with a composite score of 44.9/100 and 2 out of 5 stars, ranking #2819 out of 7,333 stocks. NUVB's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
NUVB's quality score of 37/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -64.2% (sector avg: -2.5%), gross margins of 11.2% (sector avg: 42.5%), net margins of -2260.2% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 47/100, NUVB appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 5.72x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Nuvation Bio Inc.'s investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 814.3% vs. a sector average of 5.9% and a return on assets of -34.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NUVB shows strong momentum characteristics with a score of 75/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 814.3% year-over-year, while a beta of 1.25 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
NUVB's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.25 and a debt-to-equity ratio of 14.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Nuvation Bio Inc.'s short interest score of 27/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.25), elevated leverage (D/E: 14.00x), small-cap liquidity risk. At $1.3B (small-cap), NUVB carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Nuvation Bio Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2819 of 7,333 overall (62nd percentile). Key comparisons include ROE of -64.2% trailing the -2.5% sector median and operating margins of -2568.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NUVB currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (21) would have the largest impact on the composite score.
ROE 2489% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 74% BELOW SECTOR MEDIAN
Op. Margin 199237% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Nuvation Bio Inc. (NUVB) as a Reduce with a composite score of 44.9/100 at a current price of $5.64. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (75th percentile) and value (47th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (21th percentile) and quality (37th percentile) tempers our overall conviction. We assign a No Moat rating (30/100), High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Nuvation Bio Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.9/100 places it at rank #2819 in our full 7,333-stock universe. At $1.3B in market capitalization, Nuvation Bio Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 814% and momentum in the 75th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 21th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 11% (-31.3pp vs sector) narrow to operating margins of -2569% (-2570.2pp vs sector) and net margins of -2260.2%, yielding a gross-to-net conversion rate of -20145%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $5.64, Nuvation Bio Inc. is trading near fair value based on current fundamentals. Our value factor score of 47/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 5.7x, P/S of 85.7x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 814% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (14% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (75th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 44.9/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -2260.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to Nuvation Bio Inc.. Key risk factors include current negative profitability (net margin -2260.2%). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -2260.2%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 42th percentile and quality factor at the 37th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (14% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Nuvation Bio Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-64.2%), negative profitability, weak asset returns (ROA -34.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Nuvation Bio Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Nuvation Bio Inc. receives a Reduce rating with a composite score of 44.9/100 (rank #2819 of 7,333). Our quantitative framework assigns a No Moat (30/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 44/100.
Our analysis does not support a constructive view on Nuvation Bio Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Nuvation Bio Inc. a meaningful economic moat, scoring 30/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 9/20.
The strongest moat sources are financial resilience (9/20) and growth durability (8.8/20). Interest coverage -8.6x. Rev growth 814%, 5yr history. These pillars form the core of Nuvation Bio Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and margin superiority (3/20). ROE proxy -64.2% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Nuvation Bio Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 814% expanding the revenue base. The margin cascade from 11% gross to -2569% operating to -2260.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 37th percentile.
The margin profile shows gross margins of 11%, operating margins of -2569%, net margins of -2260.2%. Return metrics include ROE of -64.2% and ROA of -34.8%. Relative to the Manufacturing sector, gross margins are 31.3 percentage points below the sector median of 43%, and ROE of -64.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 14%, revenue growth of 814%. The sector median D/E is 0%, putting Nuvation Bio Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Nuvation Bio (NUVB) stock surged approximately 50% after B. Riley Securities initiated coverage with a "Buy" rating and a $12 price target, driven by the successful launch of its lung cancer drug IBTROZI™ and strong Q3 2025 financial results. The company's leadership also presented at the Jefferies Global Healthcare Conference in London, further boosting investor interest. While the stock's valuation reflects high expectations, it is underpinned by tangible clinical data and explosive revenue growth for IBTROZI.
As the U.S. stock market kicks off February with a robust start, highlighted by the Dow Jones Industrial Average's 515-point surge and the S&P 500 nearing record highs, investors are keenly observing growth companies with significant insider ownership. In this dynamic environment, stocks like Merchants Bancorp that demonstrate strong insider confidence can be particularly appealing to investors looking for potential growth opportunities amidst favorable market conditions.
Dongfang Liu, the Chief Medical Officer of Nuvation Bio Inc. (NASDAQ:NUVB), sold 150,000 shares of Class A Common Stock for $1.17 million at a weighted-average price of $7.8217. Concurrently, Liu exercised options to acquire 150,000 shares at $2.93 each, highlighting a significant gain from the company's strong performance, with the stock up 204.9% in six months. Following these transactions, Liu directly holds 18,000 shares, and the company has a market capitalization of $2.85 billion.
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation (NASDAQ: INTC) fell sharply in today’s pre-market trading after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business. Intel shares dipped 4.8% to $41.85 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. Mesoblast Limited (NASDAQ:
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from Benzinga Pro. LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MariaDB plc (NYSE: MRDB) climbed 70.4% to $0.3850 after Progress Software announced that it is possibly considering an offer for the company. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares jumped 68.6% to $3.8099 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Nutriband Inc. (NASDAQ: NTRB) gained 33.2% to $3.9950 after the company provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Verb Technology Company, Inc. (NASDAQ: VERB) surged 30.5% to $0.3656 after the company announced that its MARKET.live entered into a formal partnership with TikTok to become a service provider for TikTok Shop and will receive a TikTok Shop Partner designation. PaySign, Inc. (NASDAQ: PAYS) gained 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results. Destiny Tech100 Inc (NASDAQ: DXYZ) rose 26.6% to $11.39 after gaining 9% on Tuesday. PAVmed Inc. (NASDAQ: PAVM) gained 19.7% to $2.4798 after the company issued business update and fourth quarter financial results. Noah Holdings Limited (NYSE: NOAH) rose 17.5% to $11.89 after the company reported fourth quarter financial results. NuScale Power Corporation (NYSE: SMR) rose 17.5% to $4.89. The ONE Group Hospitality, Inc. (NASDAQ: STKS) shares rose 17.2% to $4.70 after the company announced that it will ...
Above 50MA
37.18%
Net New Highs
+51081